NCT02003365View on ClinicalTrials.gov

Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Osteoarthritis of the Knee
Interventions
DRUG

FX006 10 mg

Extended-release formulation

DRUG

FX006 40 mg

Extended-release formulation

DRUG

TCA IR 40 mg

Immediate-release formulation

Trial Locations (3)

16635

Duncansville

42003

Paducah

75231

Dallas

Sponsors
All Listed Sponsors
lead

Pacira Pharmaceuticals, Inc

INDUSTRY